1. Home
  2. CRL vs NUVL Comparison

CRL vs NUVL Comparison

Compare CRL & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Charles River Laboratories International Inc.

CRL

Charles River Laboratories International Inc.

HOLD

Current Price

$215.40

Market Cap

8.0B

Sector

Health Care

ML Signal

HOLD

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$102.78

Market Cap

7.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRL
NUVL
Founded
1947
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Commercial Physical & Biological Resarch
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.0B
7.1B
IPO Year
2000
2021

Fundamental Metrics

Financial Performance
Metric
CRL
NUVL
Price
$215.40
$102.78
Analyst Decision
Buy
Strong Buy
Analyst Count
14
15
Target Price
$193.17
$135.00
AVG Volume (30 Days)
629.2K
525.2K
Earning Date
02-18-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,023,704,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1.68
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$91.86
$55.54
52 Week High
$217.89
$112.88

Technical Indicators

Market Signals
Indicator
CRL
NUVL
Relative Strength Index (RSI) 72.71 49.86
Support Level $194.93 $95.51
Resistance Level $217.89 $108.46
Average True Range (ATR) 5.26 3.89
MACD 0.90 -0.28
Stochastic Oscillator 87.15 53.42

Price Performance

Historical Comparison
CRL
NUVL

About CRL Charles River Laboratories International Inc.

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

Share on Social Networks: